Legend Biotech

Update in progress

LEGN (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Legend Biotech is a biopharmaceutical company that discovers, develops, manufactures, and markets novel cell therapies for oncology in the United States, China, and Europe. Its lead product, cilta-cel (CAR-T) for multiple myeloma, is partnered with Janssen. The pipeline includes autologous CAR-T candidates for various cancers and allogeneic gamma delta CAR-T and CAR-NK therapies targeting BCMA in China. It also licenses delta-like ligand 3 therapies from Novartis. Founded 2014; based in Somerset, NJ.

Company score

Sentiment: 0.28; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.03; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive